The acquired immune deficiency syndrome (AIDS) is characterized by a progressive depletion of CD4 lymphocytes. The causative agent of AIDS, the human immunodeficiency virus (HIV) is a cytopathic retrovirus. Although the mechanisms of CD4 cell loss in HIV-infected people remains unclear, recent data indicate the direct cell killing of infected cells by HIV itself is likely responsible. An accessory gene of HIV, the vpr gene, plays an important role in the cytopathic effect of HIV. In the presence of an intact vpr gene, cultures of infected cells are nearly completely killed, while cultures infected with a virus that has a mutated vpr gene survive and replicate with the same kinetics as uninfected cells. Those cells that survive infection with a wild-type virus contain vpr genes with mutations. Furthermore, expression of Vpr itself alters cell cycle progression by causing cells to accumulate in G2/M. Vpr also plays another role in the virus life-cycle by allowing the pre-integration complex to enter the nucleus of infected cells before mitosis. This property allows HIV to infect terminally differentiated macrophages, an important reservoir of virus in the body. In this application, we seek to understand the mechanism of action of Vpr. Ultimately, we hope to determine if Vpr plays a role in the decline of CD4 cells during AIDS progression. Specifically, we will use a genetic screen for vpr mutations as well as site-directed mutations to determine the correlation between the different functions of Vpr. This will allow us to make models of the roles of Vpr in HIV pathogenesis. We will also characterize the effects of Vpr and Vpx of HIV-2 on cell proliferation. Next, we will characterize the cell cycle stage(s) affected by Vpr, and analyze the relationship between normal cell cycle controls and Vpr function. We will then determine the effects of Vpr in primary cells, and specifically determine how Vpr influences the half-life of lymphocytes and macrophages. Finally, we will use a screen for suppressors of the toxic effects of Vpr in yeast to Identify host cell targets of Vpr. In this application, we seek to understand the mechanism of action of Vpr. Ultimately, we hope to determine if Vpr plays a role in the decline of CD4 cells during AIDS progression. Specifically, we will use a genetic screen for vpr mutations as well as site-directed mutations to determine the correlation between the different functions of Vpr. This will allow us to make models of the roles of Vpr in HIV pathogenesis. We will also characterize the effects of Vpr and Vpx of HIV-2 on cell proliferation. Next, we will characterize the cell cycle stage(s) affected by Vpr, and analyze the relationship between normal cell cycle controls and Vpr function. We will then determine the effects of Vpr in primary cells, and specifically determine how Vpr influences the half-life of lymphocytes and macrophages. Finally, we will use a screen for suppressors of the toxic effects of Vpr in yeast to Identify host cell targets of Vpr.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI030927-09
Application #
2886689
Study Section
AIDS and Related Research Study Section 3 (ARRC)
Program Officer
Plaeger, Susan F
Project Start
1991-08-01
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Garcia, Erin I; Emerman, Michael (2018) Recurrent Loss of APOBEC3H Activity during Primate Evolution. J Virol :
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Roesch, Ferdinand; OhAinle, Molly; Emerman, Michael (2018) A CRISPR screen for factors regulating SAMHD1 degradation identifies IFITMs as potent inhibitors of lentiviral particle delivery. Retrovirology 15:26
Adolph, Madison B; Ara, Anjuman; Feng, Yuqing et al. (2017) Cytidine deaminase efficiency of the lentiviral viral restriction factor APOBEC3C correlates with dimerization. Nucleic Acids Res 45:3378-3394
Fregoso, Oliver I; Emerman, Michael (2016) Activation of the DNA Damage Response Is a Conserved Function of HIV-1 and HIV-2 Vpr That Is Independent of SLX4 Recruitment. MBio 7:
Wittkopp, Cristina J; Adolph, Madison B; Wu, Lily I et al. (2016) A Single Nucleotide Polymorphism in Human APOBEC3C Enhances Restriction of Lentiviruses. PLoS Pathog 12:e1005865
McLaughlin Jr, Richard N; Gable, Jacob T; Wittkopp, Cristina J et al. (2016) Conservation and Innovation of APOBEC3A Restriction Functions during Primate Evolution. Mol Biol Evol 33:1889-901
Mitchell, Patrick S; Young, Janet M; Emerman, Michael et al. (2015) Evolutionary Analyses Suggest a Function of MxB Immunity Proteins Beyond Lentivirus Restriction. PLoS Pathog 11:e1005304
Matsen 4th, Frederick A; Small, Christopher T; Soliven, Khanh et al. (2014) A novel Bayesian method for detection of APOBEC3-mediated hypermutation and its application to zoonotic transmission of simian foamy viruses. PLoS Comput Biol 10:e1003493
Refsland, Eric W; Hultquist, Judd F; Luengas, Elizabeth M et al. (2014) Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet 10:e1004761

Showing the most recent 10 out of 58 publications